Hydrofarm Group (HYFM) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
2024 saw notable operational improvements, but a challenging second half, especially Q4, due to industry oversupply and retail closures led to lower sales across the supply chain.
Net sales declined 20.9% year-over-year in Q4 2024 to $37.3M, and full-year sales fell 16% to $190.3M.
Strategic focus on higher-margin proprietary brands increased their sales mix from 35% in 2020 to 56% in 2024, supporting profitability in most quarters despite industry headwinds.
Adjusted EBITDA was negative at $(7.3)M for Q4 and $(5.2)M for the year, reflecting industry headwinds and lower gross margins.
Cost management initiatives led to a 16.9% reduction in adjusted SG&A for the year, with $9M in annual savings.
Financial highlights
Q4 net sales were $37.3 million, down 20.9% year-over-year, driven by a 16.8% decrease in volume and 3.9% decline in pricing.
Q4 gross profit was $1.8 million (4.9% margin), down from $8.4 million (17.9%) last year; adjusted gross profit was $3.6 million (9.6% margin), down from $11.5 million (24.3%).
Q4 adjusted EBITDA loss was $7.3 million, attributed to lower sales and gross profit, partially offset by SG&A savings.
Cash balance at year-end was $26.1 million, with $119.3 million in term debt and $39 million in total liquidity.
Q4 free cash flow was $2.4 million; full-year free cash flow was negative $(3.2) million.
Outlook and guidance
2025 net sales expected to decline 10–20% year-over-year, but adjusted gross profit margin is projected to increase due to improved proprietary brand mix and cost savings.
Adjusted EBITDA expected to remain negative but improve versus 2024, with further SG&A reductions and operational efficiencies.
No significant non-restructuring inventory or receivable charges anticipated for 2025; free cash flow expected to improve.
Capital expenditures projected below $2M for 2025.
Latest events from Hydrofarm Group
- Net sales fell 32.7% and a major impairment drove a $242M net loss amid ongoing restructuring.HYFM
Q4 202527 Mar 2026 - Sales dropped 13% and net loss widened, but positive adjusted EBITDA and outlook reaffirmed.HYFM
Q2 20242 Feb 2026 - Gross margin improved to 19.4% as net loss narrowed and 2024 outlook was reaffirmed.HYFM
Q3 202416 Jan 2026 - Shelf registration enables up to $50M in securities for growth and strategic flexibility.HYFM
Registration Filing16 Dec 2025 - Director elections, executive pay, and auditor ratification headline the 2025 annual meeting.HYFM
Proxy Filing1 Dec 2025 - Proxy statement covers annual meeting proposals and confirms no major capital changes.HYFM
Proxy Filing1 Dec 2025 - Annual proxy statement details routine voting matters for shareholders.HYFM
Proxy Filing1 Dec 2025 - Sales and margins fell 25% as industry headwinds and restructuring drove guidance withdrawal.HYFM
Q1 202526 Nov 2025 - Sales and margins fell, but restructuring and cost cuts drove improved cash flow and outlook.HYFM
Q2 202523 Nov 2025